Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 9

PMID 39518892

Authors

Kyoung Ja Kwon

Hahn Young Kim

Seol-Heui Han

Chan Young Shin

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a progressive, degenerative brain disorder that impairs memory and thinking skills, leading to significant economic and humanistic burdens. It is associated with various neuropsychiatric symptoms (NPS) such as anxiety, agitation, depression, aggression, apathy, and psychosis. NPSs are common in patients with AD, affecting up to 97% of individuals diagnosed with AD. The severity of NPS is linked to disease progression and cognitive decline. NPS in Alzheimer's disease leads to increased morbidity, mortality, caregiver burden, earlier nursing home placement, and higher healthcare costs. Despite their significant impact, clinical research on NPS in AD is limited. In clinical settings, accurately distinguishing and diagnosing NPS related to AD remains a challenge. Additionally, conventional treatments for NPS in AD are often ineffective, highlighting the need for new therapies that target these specific symptoms. Understanding these comorbidities can aid in early diagnosis and better management of AD. In this review, we provide a summary of the various neurological and psychiatric symptoms (NPS) associated with AD and new candidates under development for the treatment of NPS based on their therapeutic targets and mechanisms. On top of the conventional NPS studied so far, this review adds recent advancements in the understanding of social functional impairment in AD. This review also provides information that can contribute to the advancement of studies and translational research in this field by emphasizing therapeutic targets and mechanisms of action focused on AD-related NPS rather than conventional mechanisms targeted in AD drug development. Above all, considering the relative lack of research in this new field despite the importance of clinical, medical, and translational research, it may increase interest in NPS in AD, its pathophysiological mechanisms, and potential therapeutic candidates such as molecules with antioxidant potential.

References

Blair H . Lumateperone: First Approval. Drugs. 2020; 80(4):417-423. DOI: 10.1007/s40265-020-01271-6. View

Rey C, Robert V, Bouisset G, Loisy M, Lopez S, Cattaud V . Altered inhibitory function in hippocampal CA2 contributes in social memory deficits in Alzheimer's mouse model. iScience. 2022; 25(3):103895. PMC: 8873612. DOI: 10.1016/j.isci.2022.103895. View

Dawson L . The central role of 5-HT6 receptors in modulating brain neurochemistry. Int Rev Neurobiol. 2011; 96:1-26. DOI: 10.1016/B978-0-12-385902-0.00001-2. View

Leser N, Wagner S . The effects of acute social isolation on long-term social recognition memory. Neurobiol Learn Mem. 2015; 124:97-103. DOI: 10.1016/j.nlm.2015.07.002. View

Chen L, Sun Y, Li J, Liu S, Ding H, Wang G . Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer's Disease Neurodegeneration. Cells. 2023; 12(23). PMC: 10705747. DOI: 10.3390/cells12232672. View

Xiong Y, Lim C . Understanding the Modulatory Effects of Cannabidiol on Alzheimer's Disease. Brain Sci. 2021; 11(9). PMC: 8472755. DOI: 10.3390/brainsci11091211. View

Willett K, Bond L, Morrill A, Lorena D, Petru I . Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder. Am J Ther. 2024; 31(1):e24-e29. DOI: 10.1097/MJT.0000000000001699. View

Ajenikoko M, Ajagbe A, Onigbinde O, Okesina A, Tijani A . Review of Alzheimer's disease drugs and their relationship with neuron-glia interaction. IBRO Neurosci Rep. 2023; 14:64-76. PMC: 9803919. DOI: 10.1016/j.ibneur.2022.11.005. View

Stam D, Rosseel S, De Winter F, Van Den Bossche M, Vandenbulcke M, Van den Stock J . Facial expression recognition deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic investigation of effects of phenotypic variant, task modality, geographical region and symptomatic specificity. J Neurol. 2023; 270(12):5731-5755. DOI: 10.1007/s00415-023-11927-4. View

10.

Ray B, Sokol D, Maloney B, Lahiri D . Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue. Sci Rep. 2016; 6:26052. PMC: 4876513. DOI: 10.1038/srep26052. View

11.

Sokol D, Lahiri D . APPlications of amyloid-β precursor protein metabolites in macrocephaly and autism spectrum disorder. Front Mol Neurosci. 2023; 16:1201744. PMC: 10548831. DOI: 10.3389/fnmol.2023.1201744. View

12.

Goldberg T, Choi J, Lee S, Gurland B, Devanand D . Effects of restriction of activities and social isolation on risk of dementia in the community. Int Psychogeriatr. 2021; 33(11):1207-1215. DOI: 10.1017/S1041610221000776. View

13.

Lyketsos C, Szekely C, Mielke M, Rosenberg P, Zandi P . Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr. 2008; 20(5):871-89. PMC: 2688723. DOI: 10.1017/S1041610208007382. View

14.

Santabarbara J, Lipnicki D, Olaya B, Villagrasa B, Bueno-Notivol J, Nuez L . Does Anxiety Increase the Risk of All-Cause Dementia? An Updated Meta-Analysis of Prospective Cohort Studies. J Clin Med. 2020; 9(6). PMC: 7355582. DOI: 10.3390/jcm9061791. View

15.

Quiroz J, Machado-Vieira R, Zarate Jr C, Manji H . Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology. 2010; 62(1):50-60. PMC: 2889681. DOI: 10.1159/000314310. View

16.

Devanand D . Management of neuropsychiatric symptoms in dementia. Curr Opin Neurol. 2023; 36(5):498-503. PMC: 10529332. DOI: 10.1097/WCO.0000000000001199. View

17.

Ruthirakuhan M, Herrmann N, Abraham E, Chan S, Lanctot K . Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev. 2018; 5:CD012197. PMC: 6494556. DOI: 10.1002/14651858.CD012197.pub2. View

18.

Cummings J, Lyketsos C, Peskind E, Porsteinsson A, Mintzer J, Scharre D . Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA. 2015; 314(12):1242-54. DOI: 10.1001/jama.2015.10214. View

19.

Wolinsky D, Drake K, Bostwick J . Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease. Curr Psychiatry Rep. 2018; 20(12):117. DOI: 10.1007/s11920-018-0978-8. View

20.

Klinedinst N, Regenold W . A mitochondrial bioenergetic basis of depression. J Bioenerg Biomembr. 2014; 47(1-2):155-71. DOI: 10.1007/s10863-014-9584-6. View